Abstract
Adjuvant chemotherapy with CMF in pathological stage II breast cancer has been shown by the Milan Group to produce a disease-free survival and overall survival advantage at 6 years in premenopausal patients (Bonadonna et al. 1978). The value of adjuvant chemotherapy in postmenopausal patients is less well established, although it seems likely to be real. It has been suggested that treatment success may well be dose related in all patients (Bonadonna and Valagussa 1981) and toxicity related (Carpenter et al. 1982). The role of adjuvant chemotherapy in node-negative patients has still to be confirmed (Senn et al. 1981).
For the Ludwig Breast Cancer Study Group; list of participants in Appendix 1
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:20–51
Bonadonna G, Valagussa P, Rossi A, Zucali R, Tancini G, Bajetta E, Brambilla C, De Lena M, Di Fronzo G, Banfi A, Rilke F, Veronesi U (1978) Are surgical adjuvant trials altering the course of breast cancer? Semin Oncol 5:450–464
Bonadonna G, Rossi A, Tancini G, Brambilla C, Marchini S, Valagussa P, Veronesi U (1981) Adjuvant treatment for breast cancer. The Milan Institute experience. Proceed was of the 3rd international conference on the adjuvant therapy of cancer. March 18–21, Tucson
Carpenter TT, Maddox WA, Laws HL, Wirtschaften DD, Soong SJ (1982) Favorable factors in the adjuvant therapy of breast cancer. Cancer 50:18–23
Deacon R, Lumb M, Perry J (1980) Inactivation of methionine syntetase by nitrous oxide. Eur J Biochem 104:419–422
DeWys WD (1972) Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. Cancer Res 32:374–379
Dudman NPB, Slowiaczek P, Tattersall MHN (1982) Methotrexate rescue by 5-methyl THF or 5-formyl THF in lymphoblastoid cell lines. Cancer Res 42:502–507
Fisher B, Slack N, Katrych D, Wolmark N (1975) Ten year follow-up of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140:528–534
Fisher B, Redmond C, Brown A, Wickerham DL, Wolmark N, Allegra J, Fischer G, Lippman M, Savlov E, Wittliff J, Fischer ER (1981) Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305:1–6
Goldie JH, Coldman AJ (1979) A mathematic model of relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727–1733
Hubay CA, Pearson OH, Marshall JS, Stellato TA, Rhodes RS, Be Banne SM (1980) Antiestrogen, cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer; a preliminary report. Surgery 87:494–501
Jungi WF, Brunner KW, Cavalli F, Martz G, Rosset G, Barrelet L (1981) Short or long term adjuvant chemotherapy for breast cancer. Proc Am Soc Clin Oncol 22:435 (Abstract C399)
Kano Y, Sakamoto S, Sakuraya K, Kuboto T, Hida K, Suda K, Takaku F (1981) Effect of nitrous oxide on human bone marrow cells and its synergistic effect with methionine and methotrexate on functional folate deficiency. Cancer Res 41:4698–4701
Ludwig Breast Cancer Study Group (1983) Severe toxicity encountered in adjuvant combination chemotherapy for breast cancer administered in the immediate post-mastectomy period. Lancet II:542–544
Nissen-Meyer R, Kjellgren K, Malmio K, Mansson B, Norin T (1978) Surgical adjuvant chemotherapy. Results with one short course with cyclophosphamide after mastectomy for breast cancer. Cancer 41:2088–2098
Nunn JF, Sharer NM, Gorchein A, Jones JA, Wickramasingha SN (1982) Megaloblastic haemopoiesis after multiple short term exposure to nitrous oxide. Lancet I:1379–1381
Schabel FM (1977) Surgical adjuvant chemotherapy of metastatic murine tumors. Cancer 40:558–568
Senn HJ, Jungi WF, Amgwerd R (1981) Chemoimmunotherapy with LMF plus BCG in node-positive and node-positive breast cancer. In: Adjuvant therapy for cancer III. Salmon SE, Jones SE (eds). Grune and Stratton, New York, 385–390
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Goldhirsch, A. (1985). Perioperative and Conventionally Timed Chemotherapy in Operable Breast Cancer. In: Metzger, U., Largiadèr, F., Senn, HJ. (eds) Perioperative Chemotherapy. Recent Results in Cancer Research, vol 98. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-82432-6_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-82432-6_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-82434-0
Online ISBN: 978-3-642-82432-6
eBook Packages: Springer Book Archive